Enavate stake in CAMP4 falls to 4.8% after sales

Enavate Sciences entities filed Amendment No. 3 to report that they beneficially own 2,495,562 shares of CAMP4 Therapeutics common stock, representing 4.8% of the class based on 51,919,321 shares outstanding as of March 4, 2026.

Accepted by SEC EDGAR 03/11/2026 - 05:57 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Enavate Sciences entities filed Amendment No. 3 to report that they beneficially own 2,495,562 shares of CAMP4 Therapeutics common stock, representing 4.8% of the class based on 51,919,321 shares outstanding as of March 4, 2026. Everest LP holds the shares directly, and Enavate Sciences GP, LLC, as general partner, shares voting and investment power. The reporting persons state they ceased to be beneficial owners of more than five percent of the common stock on March 9, 2026. In the prior sixty days, Everest LP sold multiple blocks of shares in open-market trades, including 91,699 shares on March 9, 2026 at a weighted average price of $6.69 per share and 99,639 shares on March 10, 2026 at a weighted average price of $5.83 per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Enavate currently report in CAMP4 Therapeutics (CAMP)?

Enavate-related entities report beneficial ownership of 2,495,562 shares of CAMP4 Therapeutics common stock, representing 4.8% of the class, based on 51,919,321 shares outstanding as of March 4, 2026 in the company’s Form 10-K.

When did Enavate fall below 5% ownership in CAMP4 Therapeutics stock?

The reporting persons state they ceased to be beneficial owners of more than five percent of CAMP4 Therapeutics common stock on March 9, 2026. This change is disclosed in Item 5(e) of Amendment No. 3 to their Schedule 13D filing.

Which entity actually holds CAMP4 Therapeutics shares for Enavate?

The filing states that Everest LP directly holds 2,495,562 shares of CAMP4 Therapeutics common stock. Enavate Sciences GP, LLC is general partner of Everest LP and shares voting and investment authority over these shares as described in Item 5(a).

What recent CAMP4 Therapeutics share sales did Everest LP disclose?

Within the prior sixty days, Everest LP disclosed several open-market sales, including 91,699 shares on March 9, 2026 at a weighted average price of $6.69 and 99,639 shares on March 10, 2026 at a weighted average price of $5.83 per share.

What security is covered in this Enavate Schedule 13D/A for CAMP4?

The filing covers Common Stock of CAMP4 Therapeutics Corporation with a par value of $0.0001 per share. This is the issuer’s primary equity security referenced in Item 1(a) and used for the beneficial ownership calculations in Item 5.

Who are the reporting persons in this CAMP4 Therapeutics Schedule 13D/A?

The reporting persons include Enavate Sciences GP, LLC and Everest Aggregator / Everest LP. Enavate GP is described as the general partner of Everest LP, and both entities report shared voting and dispositive power over 2,495,562 CAMP4 Therapeutics common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

CAMP4 THERAPEUTICS CORPORATION

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

James P. Boylan
Enavate Sciences, 106 W 56th Street, 8th Floor
New York, NY, 10019
(332) 275-5551

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/09/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Enavate Sciences GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,495,562.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,495,562.00

11

Aggregate amount beneficially owned by each reporting person

2,495,562.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Everest Aggregator, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,495,562.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,495,562.00

11

Aggregate amount beneficially owned by each reporting person

2,495,562.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.8 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: CAMP4 THERAPEUTICS CORPORATION
(c)	Address of Issuer's Principal Executive Offices: One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MASSACHUSETTS , 02139.
Item 1 Comment: This Amendment No. 3 (this "Amendment No. 3" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 22, 2024 and amended on September 15, 2025 and December 23, 2025 (as amended, the "Statement") by the Reporting Entities. Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 5.	Interest in Securities of the Issuer
(a)	Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon 51,919,321 shares of Common Stock outstanding as of March 4, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 5, 2026. Everest LP directly holds 2,495,562 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP.
(b)	Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
(c)	Except as set forth below, none of the Reporting Entities has effected any transactions with respect to the securities of the Issuer during the past sixty days. On January 12, 2026, Everest LP sold an aggregate of 497 shares in open market transactions at prices ranging from $6.05 to $6.20 (weighted average sales price of $6.11 per share). On January 14, 2026, Everest LP sold an aggregate of 11,228 shares in open market transactions at prices ranging from $6.00 to $6.05 (weighted average sales price of $6.00 per share). On February 25, 2026, Everest LP sold an aggregate of 7,561 shares in open market transactions at prices ranging from $4.50 to $4.62 (weighted average sales price of $4.59 per share). On February 26, 2026, Everest LP sold an aggregate of 5,413 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.54 per share). On February 27, 2026, Everest LP sold an aggregate of 2,395 shares in open market transactions at prices ranging from $4.50 to $4.72 (weighted average sales price of $4.63 per share). On March 2, 2026, Everest LP sold an aggregate of 6,926 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.52 per share). On March 9, 2026, Everest LP sold an aggregate of 91,699 shares in open market transactions at prices ranging from $6.50 to $7.15 (weighted average sales price of $6.69 per share). On March 10, 2026, Everest LP sold an aggregate of 99,639 shares in open market transactions at prices ranging from $5.55 to $6.35 (weighted average sales price of $5.83 per share).
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock.
(e)	The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on March 9, 2026.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Entities' Schedule 13D filed with the SEC on October 22, 2024).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Enavate Sciences GP, LLC

Signature:	/s/ James P. Boylan
Name/Title:	By James P. Boylan, Manager
Date:	03/11/2026

Everest Aggregator, LP

Signature:	/s/ James P. Boylan
Name/Title:	By: Enavate Sciences GP, LLC, its General Partner, By James P. Boylan, Manager
Date:	03/11/2026